On December 2, our global BD VP Dr. Yulian Zhang presented at the 10th anniversary conference of the Sino-American Pharmaceutical Professionals Association in Connecticut (SAPA-CT). Dr. Zhang showcased the immense potential of 3D printing technology in drug development and production, highlighting Triastek's groundbreaking MED technology.

With our 3D microstructure drug delivery platforms, including sustained release, colon targeting, solubility enhancement, gastric retention, and oral peptides, Triastek is at the forefront of technological advancements in the pharmaceutical industry. These platforms have been extensively researched and the feasibility has been confirmed through scientific research programs and comprehensive data.

We are excited to share that Triastek has successfully obtained four IND approvals for three self-developed 3D printed drug products in both China and the US. Our first product, T19, is based on the innovative 3D Microstructure for Delayed Release (3DμS®-DR) platform. This product has shown promising results in improving efficacy for rheumatoid arthritis through delayed release.

Currently, clinical studies for T19 are underway, and we anticipate getting NDA approval in 2025. Our team is committed to advancing the development of T19 and other 3D printed drug products, as we strive to revolutionize drug delivery and enhance patient outcomes.

Dr. Zhang stated, "Triastek is a globally-oriented enterprise since its establishment. With the deepening of our open strategy in the 2.0 era, we have accelerated our pace of globalization. We hope pharmaceutical professionals with international perspectives will join us and embark on the journey of intelligent pharmaceuticals together!"

Join us via hr@triastek.com!

About Triastek

Triastek is a global leader in 3D printing pharmaceuticals, pioneering the next generation of digital pharmaceutical processes.

Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medication through digital product development and continuous manufacturing.

Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals.

Our vision is to become the world's most influential intelligent pharmaceutical enterprise.